PD-L1 IHC in NSCLC with a global and methodological perspective

Erik Thunnissen*, Adrianus J. de Langen, Egbert F. Smit

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review


In summary, the PD-L1 biomarker discussed here highlights the importance of understanding the practice of IHC. This can be used to the patients advantage, with appropriate usage. The currently available literature on PD-L1 IHC from a methodologic point of view has not shown that different assays are comparable. The route of laboratory developed test and commercial test validation is the same: challenging and complex. Executing this process along proper methodologic lines is needed to ensure that patients receive the most accurate and representative test outcomes.

Original languageEnglish
Pages (from-to)102-105
Number of pages4
JournalLung Cancer
Publication statusPublished - 1 Nov 2017

Cite this